Personalized Support For Your PROVENGE® Patients Is Just A Call Away…
Dendreon ON Call is committed to supporting your practice AND your patients

Comprehensive Support Throughout the PROVENGE Treatment Process

  • Dendreon ON Call offers personalized PROVENGE support for your practice and patients
  • Dedicated case managers can assist with enrollment, rapid benefits verification, and patient assistance eligibility
  • Dendreon ON Call scheduling coordinators arrange a patient’s full course of therapy and make reminder calls
  • PROVENGE has robust coverage across commercial and government payers, and our reimbursement coordinators expertly provide coding, claims, and coverage support
  • Dendreon ON Call offers a secure Provider Portal to track enrollment status and patient treatment progress

A Resource for Integrating PROVENGE

Dendreon ON Call provides convenient and comprehensive tools for patients and your practices. The PROVENGE Practice Pathway Resource Guide combines information and resources into one interactive reference tool to help integrate PROVENGE Immunotherapy into your practice.

Enroll and Track Your Patients
Dendreon ON Call offers a secure and convenient Provider Portal for getting patients started with PROVENGE immunotherapy.
Contact Dendreon ON Call
To assist your practice with PROVENGE immunotherapy,
call 877-336-3736


PROVENGE® (sipuleucel-T) is an autologous cellular immunotherapy indicated for the treatment of asymptomatic or minimally symptomatic metastatic castrate-resistant (hormone-refractory) prostate cancer.


Acute Infusion Reactions: Acute infusion reactions (reported within 1 day of infusion) may occur and include nausea, vomiting, fatigue, fever, rigor or chills, respiratory events (dyspnea, hypoxia, and bronchospasm), syncope, hypotension, hypertension, and tachycardia.

Thromboembolic Events: Thromboembolic events, including deep venous thrombosis and pulmonary embolism, can occur following infusion of PROVENGE. The clinical significance and causal relationship are uncertain. Most patients had multiple risk factors for these events. PROVENGE should be used with caution in patients with risk factors for thromboembolic events.

Vascular Disorders: Cerebrovascular events (hemorrhagic/ischemic strokes and transient ischemic attacks) and cardiovascular disorders (myocardial infarctions) have been reported following infusion of PROVENGE. The clinical significance and causal relationship are uncertain. Most patients had multiple risk factors for these events.

Handling Precautions: PROVENGE is not tested for transmissible infectious diseases.

Concomitant Chemotherapy or Immunosuppressive Therapy: Chemotherapy or immunosuppressive agents (such as systemic corticosteroids) given concurrently with the leukapheresis procedure or

PROVENGE has not been studied. Concurrent use of immune-suppressive agents may alter the efficacy and/or safety of PROVENGE.

Adverse Reactions: The most common adverse reactions reported in clinical trials (≥ 15% of patients receiving PROVENGE) were chills, fatigue, fever, back pain, nausea, joint ache, and headache.

Click here for Prescribing Information.